7 results match your criteria: "Hurvitz Brain Sciences Program Sunnybrook Research Institute Toronto Ontario Canada.[Affiliation]"
Introduction: This study aimed to identify cognitive tests that optimally relate to tau positron emission tomography (PET) signal in the inferior temporal cortex (ITC), a neocortical region associated with early tau accumulation in Alzheimer's disease (AD).
Methods: We analyzed cross-sectional data from the harvard aging brain study (HABS) (= 128) and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study (= 393). We used elastic net regression to identify the most robust cognitive correlates of tau PET signal in the ITC.
Association between clinical dementia rating and clinical outcomes in Alzheimer's disease.
Alzheimers Dement (Amst)
January 2024
Department of Brain Health, Chambers-Grundy Center for Transformative Neuroscience UNLV Las Vegas Nevada USA.
Introduction: We examined associations between the Clinical Dementia Rating Scale (CDR) and function (Functional Assessment Scale [FAS]), neuropsychiatric symptoms (Neuropsychiatric Inventory Questionnaire [NPI-Q]), and cognitive impairment in Alzheimer's disease (AD).
Methods: We used data from the National Alzheimer's Coordinating Center Uniform Data Set and defined cognitively unimpaired and AD stages using CDR-global.
Results: Functional and neuropsychiatric symptoms occur as early as the mild cognitive impairment (MCI) phase.
Article Synopsis
- The ADAS-Cog is designed to measure cognitive decline in Alzheimer's patients, focusing on memory, language, and practical skills (praxis).
- A study assessing 341 participants with mild Alzheimer's over 24 months found that while language items were the most reliable, many other items, particularly in memory and praxis, were inconsistent.
- The findings indicate that the ADAS-Cog has limitations in accurately tracking cognitive decline over time due to the varying reliability and types of information captured by its items.
Introduction: Physical activity (PA) promotes resilience with respect to cognitive decline, although the underlying mechanisms are not well understood. We examined the associations between objectively measured PA and resting-state functional connectivity magnetic resonance imaging (rs-fcMRI) across seven anatomically distributed neural networks.
Methods: rs-fcMRI, amyloid beta (Aβ) positron emission tomography (PET), PA (steps/day × 1 week), and longitudinal cognitive (Preclinical Alzheimer's Cognitive Composite) data from 167 cognitively unimpaired adults (ages 63 to 90) were used.
Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring".
Mov Disord Clin Pract
May 2022
Division of Neurology, Department of Medicine University of Toronto Toronto Ontario Canada.
Background: Progressive supranuclear palsy (PSP)-pallido-nigro-luysian atrophy (PNLA) is a neuropathological entity thought to be a variant of classic PSP. Clinical features and pathologic hallmarks are the same in both conditions; however, age and order of symptom onset, disease duration and prognosis, and distribution and density of pathology differentiate the 2 entities.
Objectives: This study presents a PSP-PNLA case confirmed pathologically with a clinical presentation of hemichorea/ballism, spasticity, progressive hemiparesis, and a frontal behavioral syndrome with relative cognitive sparing early in the disease course.
Introduction: Studies suggest associations between proton pump inhibitors (PPIs) and dementia risk; however, many neither considered histamine-2 receptor antagonists (H2RAs) nor baseline cognitive status.
Methods: Participants (National Alzheimer's Coordinating Center Database; 2005-2021) using a PPI or H2RA were compared. Covariate-adjusted Cox regression was used to estimate hazard ratios (HR) for progression from normal cognition to mild cognitive impairment (MCI), and from MCI to dementia over 5 years.